Recursion Pharmaceuticals (RXRX) Assets (2020 - 2026)

Recursion Pharmaceuticals (RXRX) has 7 years of Assets data on file, last reported at $1.3 billion in Q1 2026.

• For the quarter ending Q1 2026, Assets rose 2.63% year-over-year to $1.3 billion; the trailing twelve-month figure through Mar 2026 stood at $1.3 billion (up 2.63% YoY), and the FY2025 full-year result was $1.5 billion, up 1.76% from the prior year.
• Assets for Q1 2026 stood at $1.3 billion, down from $1.5 billion in the prior quarter.
• Across five years, Assets topped out at $1.5 billion in Q4 2025 and bottomed at $557.8 million in Q1 2024.
• The 5-year median for Assets is $726.5 million (2024), against an average of $919.3 million.
• The widest annual swing landed in 2022, when Assets surged 170.03%; it then slipped 14.56% in 2023.
• A 5-year view of Assets shows it stood at $701.3 million in 2022, then declined by 6.79% to $653.7 million in 2023, then soared by 121.6% to $1.4 billion in 2024, then climbed by 1.76% to $1.5 billion in 2025, then slipped by 9.13% to $1.3 billion in 2026.
• The last three Assets figures came in at $1.3 billion (Q1 2026), $1.5 billion (Q4 2025), and $1.4 billion (Q3 2025), per Business Quant data.

Peer Comparison